Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by nomoneyon Jul 26, 2019 6:59pm
150 Views
Post# 29966102

News

NewsLast post failed miserably! 

BROADWAY GOLD MINING LTD. ANNOUNCES PROPOSED ACQUISITION OF MIND MEDICINE, INC. AND RELATED FINANCING TRANSACTIONS

Broadway Gold Mining Ltd. has entered into a binding letter of intent with Mind Medicine Inc., a privately held issuer incorporated under the laws of Delaware (MMED), which outlines the general terms and conditions pursuant to which Broadway and MMED have agreed to complete a transaction that will result in a reverse takeover of Broadway by the current shareholders of MMED. The LOI was negotiated at arm's length and is effective as of July 26, 2019.

MMED is assembling a compelling drug development pipeline of psychedelic inspired medicines planning or undertaking FDA trials. The company plans to grow its pipeline of psychedelic inspired medicines through acquisitions, joint ventures and collaborative development agreements.

MMED is developing a transformational treatment for opioid addiction to address the growing U.S. opioid crisis. MMED holds 100% of right, title and assets connected with the drug development project for 18-methoxycoronaridine or 18-MC (the "18-MC Program"), a synthetic congener of the naturally-occurring psychedelic compound ibogaine.

Bullboard Posts